Drugs / HS-10529
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06963398 | May 2025 → Apr 2029 expected | cancer | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2025-04-16 | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Regulatory HANSOH PHARMA RECEIVES THE CLINICAL TRIAL APPROVAL FROM NMPA FOR HS-10529 IN ADVANCED SOLID TUMORS hspharm.com ↗ |
| 2025-04-16 | Hansoh BioMedical R&D Company | Regulatory 翰森制药HS-10529获批临床，拟治疗KRAS G12D突变晚期实体瘤 hansoh.cn ↗
2025年4月15日，翰森制药集团有限公司（以下简称“翰森制药”，03692. HK）宣布，公司自主研发的1类新药HS-10529片获国家药品监督管理局(NMPA)签发的药物临床试验批准通知书，拟开发治疗KRAS G12D突变的晚期实体瘤. |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2025-04-16 | Jiangsu Hansoh Pharmaceutical Co., Ltd. | HANSOH PHARMA RECEIVES THE CLINICAL TRIAL APPROVAL FROM NMPA FOR HS-10529 IN ADVANCED SOLID TUMORS hspharm.com ↗ |
| 2025-04-16 | Hansoh BioMedical R&D Company | 翰森制药HS-10529获批临床，拟治疗KRAS G12D突变晚期实体瘤 hansoh.cn ↗ |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HS-10529 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06963398 ↗ |
| Action | Inhibit | “inhibitor of KRAS G12D” NCT06963398 ↗ |
| Modality | Small molecule | “small molecular inhibitor” NCT06963398 ↗ |
| Route | Oral | “HS-10529 is an oral” NCT06963398 ↗ |
| Target | KRAS | “inhibitor of KRAS G12D” NCT06963398 ↗ |